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The maintenance of genetic stability depends on the ﬁne-tuned initiation and termination of pathways
involved in cell cycle checkpoints and DNA repair. Here, we describe a new pathway that regulates check-
point kinase 1 (CHK1) activity, a key element controlling both checkpoints and DNA repair. We show that
the ubiquitin-speciﬁc peptidase 1 (USP1) deubiquitinase participates in the maintenance of both total and
phosphorylated levels of CHK1 in response to genotoxic stress. We establish that USP1 depletion stimulates
the damage-speciﬁc DNA-binding protein 1-dependent degradation of phosphorylated CHK1 in both a mono-
ubiquitinylated Fanconi anaemia, complementation group D2 (FANCD2)-dependent and -independent
manner. Our data support the existence of a circuit in which CHK1 activates checkpoints, DNA repair and pro-
liferating cell nuclear antigen and FANCD2 monoubiquitinylation. The latter two events, in turn, switch off
activated CHK1 by negative feedback inhibition, which contributes to the downregulation of the DNA
damage response. This pathway, which is compromised in the cancer-prone disease Fanconi anaemia
(FA), likely contributes to the hypersensitivity of cells from FA patients to DNA damage and to the clinical
phenotype of the syndrome; it may also represent a pharmacological target to improve patient care and
develop new cancer therapies.
INTRODUCTION
Genetic stability in response to DNA damage and stalled
replication forks depends on the relatively well-described
interconnected action of cell cycle checkpoints and DNA
repair mechanisms (1,2). A crucial role in the maintenance
of the genomic stability is played by the signalling
pathway initiated by replication protein A (RPA)-coated
single-strand DNA stretches that are generated during repli-
cation fork stalling or via the resection of double-strand
breaks that activate S and G2/M checkpoints through the
ataxia telangiectasia and RAD3 related (ATR)-mediated
phosphorylation of checkpoint kinase 1 (CHK1). This phos-
phorylation triggers CHK1 activation and downstream
CHK1-mediated events that regulate cell cycle arrest and
DNA repair (2,3). In addition to its role in cell cycle
regulation, CHK1 is functionally or directly involved in
proliferating cell nuclear antigen (PCNA) and Fanconi
anemia, complementation group D2 (FANCD2) monoubiqui-
tinylation (4–7) and in the full activation of the homologous
recombination (HR) protein RAD51 (8). Consequently, it is
likely that CHK1 activity requires a ﬁne-tuned regulation
to optimize the cellular response to DNA damage. Indeed,
studies in yeast reported that shortening or delaying CHK1
activation results in cellular hypersensitivity to DNA
damage despite an opposite effect on mitotic entry (9).
Recent studies demonstrated that CHK1 is part of both
checkpoint initiation and termination. CHK1 phosphorylation
may both participate in CHK1 activation and promote its
degradation. The turning off of CHK1 activity can be
mediated by the proteasomal degradation of its S345 phos-
phorylated form following cullin 4A (CUL4A)- or cullin 1
(CUL1)-dependent ubiquitinylation (10,11). Alternatively,
CHK1 signalling could be restrained by the targeted protea-
somal degradation of the adaptor protein CLASPIN.
CLASPIN, which is initially required for optimal CHK1
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Advance Access published on March 9, 2011phosphorylation by ATR, is ubiquitinylated by the E3 ligase
complex associating the Skp1-Cul1-F-box proteins to the
beta-transducin repeat containing protein (SCFbTrcp), a
process impeded by the deubiquitinase ubiquitin speciﬁc
peptodase 7 (USP7) (12). Indeed, CLASPIN degradation
contributes to checkpoint termination, preventing ATR-
mediated CHK1 phosphorylation. Consequently, full check-
point termination is the result of the coordinated action of
all these distinct pathways. Because CHK1 expression has
been associated with anticancer therapy resistance (13–16),
a better understanding of the different mechanisms involved
in CHK1 signalling may reveal new predictive biomarkers of
tumour responsiveness and has major implications for cancer
therapy choices.
Rare genetic diseases, such as Fanconi anaemia (FA) syn-
drome (17), which are caused by inherited recessive mutations
in DNA damage response (DDR) genes, represent fundamen-
tal models to approach how cells cope with DNA lesions and
replicative stress (18). FA patients present with aplastic
anaemia, developmental defects and a predisposition to
cancer (19). No fewer than 15 FANC proteins are
required for cellular and chromosomal resistance to inter-
strand DNA crosslinks (ICLs) (19–25). At least eight
FANC proteins (FANCA/B/C/E/F/G/L/M) are assembled
into the FANCcore complex that catalyses the monoubiquiti-
nylation of FANCD2 (mono-Ub-FANCD2) and FANCI
(mono-Ub-FANCI) during S phase or in response to DNA
damage, promoting their chromatin localization, assembly in
subnuclear foci and interaction with the FANCD2/FANCI-
associated nuclease 1 protein (24,26–28). The other FANC
proteins, FANCJ/BRIP1, FANCD1/BRCA2 and FANCN/
PALB2, act in parallel or downstream of FANCD2, complet-
ing the so-called FANC pathway. The FANC pathway partici-
pates in the regulation of HR (26–28) and is required for ICL
resistance by direct or functional interactions with partners,
such as ATR, BReast CAncer predisposition gene/protein 1
(BRCA1), bloom syndrome-mutated protein and the meiotic
recombination 11 homolog (MRE11)–RAD50–Nibrin
(NBN or NBS1) complex (29–37). Recently, RAD51C
mutations have been reported in one family of patients with
an FA-like phenotype, supporting the link between FA, HR
and ICL repair (38). FA cells undergo a longer G2 phase
(39) and an abnormal delay in S and G2 transit following
DNA damage (40). The accumulation of FA cells in late
S/G2 following treatment with ICL-inducing agents is depen-
dent on CHK1 activity and its ATR-dependent phosphoryl-
ation (5). The accumulation of FA cells with a 4N DNA
content and CHK1 hyperphosphorylation could be the conse-
quence of a normal checkpoint response in cells with DNA
damage hypersensitivity (41). Alternatively, the accumulation
of FA cells in late S/G2 could also represent a defect in reco-
vering from the ATR/CHK1 checkpoint in response to
ICL-inducing agents. To test this hypothesis and gain
insight into the mechanisms involved in CHK1 regulation,
we analysed the activation of CHK1 in cells expressing a con-
stitutively ‘activated’ FANC pathway by knocking down the
deubiquitinase ubiquitin-speciﬁc peptidase 1 (USP1), which
restrains the monoubiquitinylation of FANCD2/FANCI
(42,43). Following this approach, we discovered
USP1-regulated and damage-speciﬁc DNA-binding protein 1
(DDB1)-dependent mechanisms that are involved in the
downregulation of activated CHK1 in human cells in both a
FANC pathway-dependent and -independent manner.
RESULTS
USP1 depletion impacts the stability and phosphorylation
of CHK1 in both a monoubiquitinylated
FANCD2-dependent and -independent manner
FANC pathway deﬁciency is associated with DNA damage-
induced CHK1 hyperphosphorylation (5), suggesting that
FANCD2 monoubiquitinylation could restrain checkpoint sig-
nalling. Thus, we hypothesized that a higher constitutional
level of mono-Ub-FANCD2 should result in the opposite,
i.e. a lower level of phosphorylated CHK1 (p-CHK1). In
order to increase FANCD2 monoubiquitinylation and
address the involvement of the FANC pathway in CHK1 regu-
lation, we depleted the USP1 deubiquitinase using siRNA in
U2OS and HeLa cells. As expected (42,44), USP1 downregu-
lation induced higher levels of both mono-Ub-FANCD2 and
mono-Ub-PCNA in the absence of genotoxic stress (Fig. 1A
and D). In U2OS cells, USP1 depletion was consistently
associated with a clear reduction in the steady-state level of
the CHK1 protein (Fig. 1A and B). In HeLa cells, the observed
effects of USP1 depletion on the steady-state level of CHK1
were more variable (Fig. 1C and D). Nevertheless, quantitative
analysis of seven independent experiments indicated that the
CHK1 levels in USP1-deﬁcient HeLa cells were signiﬁcantly
lower than in USP1-proﬁcient HeLa cells (Fig. 1E, P ,
0.05). Using U2OS cells transiently transfected with a
CHK1–FLAG construct (Supplementary Material,
Fig. S1A), we corroborated the observation that the decrease
in CHK1 steady-state levels was caused by USP1 downregula-
tion. The CHK1 steady-state decrease was also observed with
an unphosphorylatable 2S/A mutant CHK1–FLAG protein
(Supplementary Material, Fig. S1A); for this mutant,
p-CHK1 is not a prerequisite for its own downregulation.
Co-depletion of USP1, together with the FANCcore complex
proteins FANCC or FANCD2, rescued the steady-state level
Figure 1. USP1 depletion speciﬁcally downregulates p-CHK1 and protein levels. (A) Untreated U2OS cells were lysed 72 h after transfection with the indicated
siRNAs. The lysates were analysed by western blot using the indicated antibodies. (B) U2OS cells transfected with the indicated siRNA were treated with 2 mg/
ml/1 h of MMC and lysed 20 h after treatment. The lysates were analysed by western blot using the indicated antibodies. (C) Two days after transfection with the
indicated siRNAs, HeLa cells were treated for 1 h with the reported dose of MMC and washed before the addition of pre-warmed complete medium. Cells were
lysed 20 h later, and the lysates were analysed by western blot using the indicated antibodies. (D) HeLa cells were treated with 5 mg/ml/1 h of MMC 2 days after
siRNA transfection, and proteins were extracted 20 h after treatment to examine the activation of several DDR proteins by immunoblotting. (E) Quantiﬁcation of
the ratio of CHK1 to actin, p345CHK1 to CHK1 and p345CHK1 to actin in HeLa cells treated with 5 mg/ml/1 h of MMC and lysed 20 h later. Values represent
the mean and SD of three (MMC treatment) to seven experiments (untreated). Student’s t-test was used: ∗P , 0.05, ∗∗P , 0.01. (F) 293T cells stably expressing
a chicken FANCD2-KR-ubiquitin fusion (clone Ub2) or FANCD2-KR-monoubiquitin fusion (clone mUb3) were treated with HU and lysed at the end of the
treatment (2 mM for 30 min) or UV (5J) and lysed 1 h after irradiation, and the phosphorylation of CHK1 and H2AX was analysed by immunoblotting.
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FANCD2 could be a major event involved in USP1-dependent
regulation of CHK1 steady-state levels.
Subsequently, we exposed the cells to the DNA cross-linking
agentmitomycinC(MMC)ortoultravioletC(UVC)toanalyse
the behaviour of DNA damage-induced p-CHK1 in USP1-
depleted cells. USP1 depletion was associated with a consistent
and signiﬁcant reduction in the level of phosphorylated
S345-CHK1inbothU2OSandHeLacells(Fig.1B–EandSup-
plementary Material, Fig. S1B). More importantly, the reduced
phosphorylation of CHK1 observed in USP1-depleted cells
appeared to be highly speciﬁc. Indeed, both the DNA
damage-induced phosphorylation and the expression of other
ATR/ataxia telangiectasia-mutated protein (ATM) targets,
including NBN, RPA32, RAD17 and structural maintenance
chromosome 1 (SMC1), were not modiﬁed by USP1 depletion
(Fig. 1C and D). Moreover, depletion of the FANCcore
complex component FANCA, which is necessary for
FANCD2 monoubiquitinylation, rescued p-CHK1 in
USP1-depleted cells exposed to MMC or UVC (Fig. 1D and
Supplementary Material, Fig. S1B). Thus, FANC pathway
proﬁciency and FANCD2 monoubiquitinylation may be
requiredfortheobservedeffectsofUSP1depletiononp-CHK1.
To directly observe an active role for monoubiquitinylated
FANCD2 in CHK1 downregulation, we stably expressed a con-
stitutively monoubiquitinylated chicken form of FANCD2 (45)
in HEK293T cells (Fig. 1F). Ectopic expression of
mono-Ub-FANCD2slightlyincreasedp-CHK1andphosphory-
lated histone 2 AX (gH2AX) levels, revealing that cells that
constitutively express monoubiquitinylated FANCD2 undergo
DNA stress and activate a DDR response. Nevertheless, in
responsetogenotoxicstress,celllinesoverexpressingmonoubi-
quitinylated FANCD2 showed lower levels of both phosphory-
lated and unphosphorylated CHK1. In contrast, the increase in
the gH2AX level was similar in all cell lines. These
observationssupport the notion that FANCD2 monoubiquitiny-
lation speciﬁcally participates in the downregulation of CHK1
expression/activity.
To support the ﬁnding that mono-Ub-FANCD2 is a key
element controlling CHK1 level/phosphorylation, we analysed
the behaviour of a CHK1–FLAG construct stably expressed
in MRC5 ﬁbroblasts following deprivation of either USP1
or FANCD2 (Fig. 2A). Again, USP1 depletion was
associated with increased FANCD2 monoubiquitinylation and
downregulation of CHK1. Notably, in contrast to USP1
depletion, FANCD2 downregulation induced a higher level
of CHK1–FLAG, and a fraction of this protein appeared to
be phosphorylated (Fig. 2A). Moreover, we analysed CHK1
behaviour following MMC exposure in the chicken DT40
parental cell line, FANCD2 knock-out (KO) DT40 cells,
FANCD2 KO DT40 cells ectopically corrected with a wild-
type FANCD2 and FANCD2 KO DT40 cells expressing the
FANCD2 non-monoubiquitinylable lys (K) 563 arg (R) (KR)
form (Fig. 2B). FANCD2-deﬁcient DT40 cells showed a
clear hyperphosphorylation of CHK1, which was rescued
by the expression of the wild-type FANCD2 gene but not
by the expression of the FANCD2-KR form. Notably, in
‘corrected’ DT40 cells, the level of CHK1 was also clearly
reduced when compared with that of the KO counterpart.
Altogether, these observations validate the negative role of
the activated FANC pathway in both CHK1 stabilization
and phosphorylation.
Finally, to ascertain if elements other than mono-Ub-
FANCD2participateinUSP1-mediatedCHK1downregulation,
we depleted USP1 in FA-C, FA-G and FA-D2 ﬁbroblasts
(Fig. 2C). Depletion of USP1 in cells derived from FA patients
resulted in decreased CHK1 levels and phosphorylation,
suggesting that mono-Ub-FANCD2 is not the only USP1
target involved in CHK1 regulation and that the germline-
derived inactivation of the FANC pathway in FA
patient-derived cells uncovered or selected other pathways
to compensate for their intrinsic deﬁciency and assure cell
survival.
In conclusion, using several approaches and cellular
models, USP1 depletion speciﬁcally affects the steady-state
levels and the phosphorylation of CHK1 without perturbing
ATR signalling following both FANC pathway-dependent
and -independent mechanisms.
USP1 depletion impacts CHK1 independently of both
the cell cycle and DNA repair
Because CHK1 is a cell cycle regulated and DNA damage
checkpoint protein, we asked whether (a) the downregulation
of CHK1 in USP1-depleted cells is an experimental artefact
resulting from modiﬁcations of the cell cycle and/or altered
DNA repair capabilities caused by USP1 depletion and (b)
USP1 depletion modiﬁes the G2 checkpoint in response to
DNA damage.
We ﬁrst examined the cell cycle distribution in USP1-
depleted cells. In accordance with published data on
Usp1
2/2 mouse embryonic ﬁbroblasts (MEFs) (46), USP1
depletion had no major effects on the cell cycle progression
in unchallenged cells (Fig. 3A and B). Consequently, the
lower level of CHK1 in USP1-depleted cells is not merely a
consequence of cell accumulation in G1.
Then we monitored cell cycle recovery in response to MMC
in both U2OS and HeLa cells. As reported in Figure 3A,
USP1-depleted U2OS cells re-enter the cell cycle more
rapidly than USP1-proﬁcient cells, suggesting that USP1
depletion could accelerate recovery from the G2 checkpoint.
In contrast, as predicted from studies with Usp1
2/2 MEFs
(46), USP1-depleted HeLa cells showed an increased
MMC-induced G2/M content compared with USP1-proﬁcient
cells (Fig. 3B). Because U2OS and HeLa cells differ in their
p53 status, we repeated experiments in the presence of the
p53 inhibitor piﬁthrin-a, and we observed no difference in
the response (data not shown). Consequently, the differences
between U2OS and HeLa cells seem to be independent of
their p53 status. Western blot analysis of the two downstream
cellular checkpoint kinases CHK1 and CHK2 revealed major
differences between the HeLa and U2OS cells (Fig. 3C).
HeLa cells showed a higher level of phosphorylated CHK1
and CHK2; this result could support the prolonged G2/M
checkpoint when CHK1 signalling decreases as a result of
USP1 depletion. The observed differences in CHK2 phos-
phorylation between HeLa and U2OS cells appeared to
be linked to higher basal levels of CHK2, which appeared
slightly phosphorylated as a consequence of USP1 depletion
(Supplementary Material, Fig. S1C). Moreover, data from
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2/2 MEFs support our observations that p-CHK2
increases signiﬁcantly in USP1-depleted HeLa cells following
MMC (46). Notably, although the authors did not stress this
point in their article, the p-CHK1 level is lowered in response
to MMC in Usp1
2/2 MEFs, as we report here. Thus, CHK1
downregulation in USP1-depleted cells is not a consequence
of cell cycle modiﬁcations and cannot be generally implicated
in the exit or recovery from the S or G2/M checkpoints.
Next, we asked whether CHK1 dephosphorylation and/or
degradation in USP1-depleted cells are the consequences of
increased DNA repair capabilities. To determine whether
USP1 depletion modiﬁes the intrinsic DNA repair capabilities
of DNA-damaged cells, we analysed by dot blot the repair kin-
etics of 6–4 pyrimidine–pyrimidone (6-4 PP) lesions induced
by UVC exposure. As presented in Figure 4A, 6-4 PP were
eliminated with equal kinetics in both USP1-proﬁcient and
-deﬁcient cells, meaning that the DNA repair pathways
involved in the elimination of this lesion work normally in
the absence of USP1.
FANCD2 and PCNA monoubiquitinylation, as well as
FANCD2 redistribution in sub-nuclear foci, is considered
mandatory for cellular resistance to stalled replication forks.
Consequently, the reduction in p-CHK1 and/or stability fol-
lowing DNA damage could be the normal behaviour of cells
in which USP1 depletion results in enhanced FANCD2 or
PCNA activity as a consequence of higher levels of their
monoubiquitinylated forms (42). However, more recent data
in avian DT40 cells (47) and mice (46) demonstrated a cellular
hypersensitivity to MMC in the absence of USP1. In
accordance with these results, we observed a defect in
FANCD2 foci formation in USP1-depleted human cells
(Fig. 4B and C). Importantly, defective FANCD2 relocaliza-
tion was not the consequence of an impaired formation of
gH2AX foci, which are required for FANCD2 assembling in
subnuclear foci (48) (Fig. 4B). Hence, as predicted by data
obtained in chicken and mice (46,47), this result suggests
that FANCD2 undergoes a ﬁnely regulated ubiquitinylation/
deubiquitinylation cycle to perform its physiological role
and be recruited to and accumulate in nuclear foci. Conse-
quently, this challenges the idea that enhanced DNA repair
activity by mono-Ub-FANCD2 is responsible for the weaker
CHK1 activation observed in USP1-depleted cells.
The most obvious conclusion of our data (Figs 1 and 4)i s
that CHK1 dephosphorylation and/or degradation in USP1-
depleted cells is not caused by increased DNA repair capabili-
ties in USP1-deﬁcient cells but is directly linked to USP1
downregulation.
USP1 limits DDB1-dependent degradation of CHK1
Multiple pathways and proteins are involved in CHK1 regu-
lation (49). Among these players, the adaptor protein
CLASPIN appears to be a master regulator of CHK1 activity
(50). We observed that the siRNA-mediated depletion of
CLASPIN strongly reduced UVC-induced p-CHK1 but not
CHK1 protein levels (Fig. 5A). Compared with CLASPIN
depletion, USP1 depletion affected both the CHK1 steady-state
level and phosphorylation without discernible effects on
Figure 2. USP1 depletion and FANCD2 monoubiquitinylation have implications in CHK1 downregulation. (A) MRC5 ﬁbroblasts stably expressing CHK1–
FLAG were transfected with the indicated siRNAs and lysed 72 h later. CHK1–FLAG was then immunoprecipitated, and its phosphorylation was analysed
by western blot. (B) p-CHK1 and levels as observed in untreated and MMC-exposed DT40 cells. Fancd2ko indicates the cells carrying knockout Fancd2
alleles; +FANCD2 indicates previous cells (Fancd2ko) transfected with a wt Fancd2 (i.e. Fancd2 corrected); and +KR indicates Fancd2ko cells expressing
a Fancd2 KR mutant form. Proteins were isolated 6 h after treatment with 100 ng/ml of MMC and analysed by western blot with the indicated antibodies.
(C) FA-D2, FA-G and FA-C human ﬁbroblasts were tranfected with USP1-siRNA. MMC was added 48 h later at 2 mg/ml for 1 h and cells were lysed 24 h
later. The lysates were analysed by western blot with the indicated antibodies.
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Interestingly, co-depletion of USP1 and CLASPIN had an addi-
tive effect on both UVC-induced p-CHK1 and CHK1 protein
levels. Altogether, these results suggest that CLASPIN is not
an intermediary player downstream of USP1 in the regulation
of CHK1. On the contrary, our data suggest that CLASPIN-
dependent and USP1-regulated events work on convergent
pathways to turn on and restrain CHK1 activation.
Genotoxic stresses may promote the degradation of phos-
phorylated CHK1 in a Cul1- and/or Cul4A-dependent manner
(51). During replication, a fraction of CHK1 is indeed polyubi-
quitinylated by a CUL4A/DDB1-containing E3 ligase and is
subsequently degraded by the proteasome (10). Hence, we
directly tested the role of DDB1 in CHK1 stability by silencing
italoneorinadditiontoUSP1.Curiously,forunknownreasons,
DDB1 depletion reduced USP1 steady-state levels (Fig. 5B).
Nevertheless, the reduced level of USP1 in DDB1-depleted
cells appeared sufﬁcient to deubiquitinylate FANCD2
and maintain a normal ratio of FANCD2-L to
FANCD2-S. Co-depletion of DDB1 with USP1 nearly abro-
gated the reduced stability and phosphorylation of CHK1
observed following the simple depletion of USP1 in MMC-
and UVC-treated cells (Fig. 5B). Moreover, FANCD2 monou-
biquitinylation in USP1-depleted cells was not modiﬁed by
the depletion of DDB1, suggesting that downregulation of
CHK1 in USP1-depleted cells requires DDB1 downstream
of FANCD2. In agreement with the hypothesis that phosphory-
latedCHK1isubiquitinylatedandsubsequentlydegradedinthe
absence of USP1, treatment with the proteasome inhibitor
MG-132 could increase the level of CHK1 in USP1-depleted
cells but not in control cells (Fig. 5C). However, because
MG-132 could strongly reduce mono-Ub-FANCD2 [(52) and
data not shown], the restoration of CHK1 levels could be the
consequence of its blocked degradation, the loss of FANCD2
monoubiquitinylation or both. Nevertheless, this result demon-
strates that CHK1 downregulation is the consequence of a
rapidly reversible mechanism, likely proteasomal degradation.
Importantly, the already described interaction between
Figure 3. USP1 depletion differentially affects the accumulation in late S/G2 of U2OS and HeLa cells exposed to MMC. Forty-eight hours post-transfection with
USP1 siRNA, U2OS (A) and HeLa (B) cells were treated with 15 ng/ml or 5 ng/ml of MMC, respectively, for 48 h before ﬁxation and analysis by ﬂow cyto-
metry. (C) HeLa and U2OS cells were transfected with USP1 siRNAs, treated with 1 mg/ml/1 h of MMC and lysed 20 h later. The lysates were analysed by
western blot using the indicated antibodies. Red Ponceau staining of the membrane was used as a loading control.
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depleted HEK293T cells (Fig. 5D), which was consistent with
the idea that CHK1 degradation is linked to DDB1. Similar
results were obtained with exogenous CHK1–FLAG (data not
shown). It is important to note that USP1 depletion neither
reduced the steady-state level of another known DDB1 target,
chromatin licensing and DNA replication factor 1 (CDT1)
(53), nor enhanced its DNA damage-induced degradation,
suggesting that the DDB1/CUL4A machinery is not simply
overactive in USP1-depleted cells (Fig. 5E and F). Altogether,
our results suggest that USP1 depletion speciﬁcally promotes
thedegradationofphosphorylatedCHK1inaDDB1-dependent
manner.
DISCUSSION
We present evidence that the USP1 deubiquitinase controls a
feedback loop that limits CHK1 activity to rescue DNA-
damaged cells. A fully proﬁcient DDR cell activates a response
to overcome the difﬁculties imposed by spontaneously arising
and genotoxin-induced delayed or stalled DNA replication
forks. CHK1 participates in this response by both delaying
cell cycle progression and participating in DNA repair. CHK1
is indeed required for the monoubiquitinylation of PCNA and
FANCD2, which is involved in the resolution of replicative
stress. ATR-mediated phosphorylation of CHK1 may start a
sequence of events that simultaneously initiates and limits
checkpointsthroughthetargeteddegradationofphosphorylated
CHK1 (11,51). Similarly, the full activation of both FANCD2
and PCNA, inaddition to the resolution ofDNA replication dif-
ﬁculties, could also participate in cell recovery from cell cycle
checkpoints. We propose that the stimulation of CHK1 degra-
dation by mono-Ub-FANCD2 represents a feedback mechan-
ism that contributes to the recovery of DNA-damaged cells
(Fig. 5G). This feedback could participate in the extinction of
FANCD2 and RAD51, which is under the control of p-CHK1
(4–6,8), limiting HR events that could be toxic for the cells.
In this regard, the compromised HR efﬁciency of USP1-
depleted cells could be the consequence of FANCD2 dysfunc-
tion (46), weaker CHK1 activity (8) or both. Our data suggest
that DDB1-dependent degradation of phosphorylated CHK1
could be one of the mechanisms explaining these ﬁndings.
The regulation of the DDB1/CUL4A-based E3 ligases is a
complex process that requires the presence of DDB1 and
CUL4-associated factors (DCAFs) for the speciﬁc targeting of
various substrates of this ubiquitin ligase (54). USP1 depletion
speciﬁcally affects CHK1. Consequently, it is tempting to
speculate that mono-Ub-FANCD2 promotes the association of
the yet unidentiﬁed CHK1-speciﬁc DCAF with DDB1 and/or
CHK1, thereby enhancing CHK1 degradation and inactivation.
It is difﬁcult to determine whether CHK1 regulation
depends on FANCD2, FANCI or monoubiquitinylated
FANCD2/FANCI dimer, and we cannot exclude a role for
PCNA or other presently unknown targets of USP1 in the
CHK1 control. A PCNA/FANCD2 interaction has been
recently identiﬁed, and this interaction may be required for
proﬁcient FANCD2 monoubiquitinylation (55,56). Thus,
PCNA could participate in the control of p-CHK1 via its
action on FANCD2. However, without excluding this possi-
bility, the observation that USP1 depletion in FA cells has
an effect on phosphorylation/stability of CHK1 indicates that
mono-Ub-PCNA could inﬂuence CHK1 levels independently
from its role in FANCD2 monoubiquitinylation.
We propose that the accumulation of 4N DNA content fol-
lowing ICL-inducing agents in FA cells (57) is a consequence
of both defective DNA repair and a failure in recovering from
checkpoint arrest through the inhibition of CHK1. Our data
predict that FA cells, which cannot monoubiquitinylate
FANCD2, display overactive CHK1. Indeed, Gautier and col-
leagues (58) observed more p-CHK1 at the basal level in
FANCA-deﬁcient cells compared with FANC-proﬁcient
cells, a phenotype that is expected to result from compromised
DDB1-dependent degradation of phosphorylated CHK1. In
agreement with this, transient depletion of FANCD2 strongly
Figure 4. USP1 depletion does not affect the repair of UVC-induced DNA
lesions and does not improve FANCD2 foci formation. (A) HeLa cells trans-
fected with Ctrl or USP1 siRNAs were treated with UVC (10 J/m
2), and
genomic DNA was prepared at the indicated times. Dot blots were performed
with antibodies against 6-4 PP. DNA was then stained with an antibody recog-
nizing single-stranded DNA. (B) Immunoﬂuorescence analysis of the gH2AX
(green) and FANCD2 (red) foci in Ctrl and USP1-siRNA-transfected cells
treated with MMC (200 ng/ml for 24 h). Nuclei were stained with DAPI.
Right images represent the merge of the three colours. (C) Quantiﬁcation
of cells with more than ﬁve FANCD2 nuclear foci in control-
and USP1-siRNA-transfected cells left untreated and/or exposed to MMC
(200 ng/ml) and ﬁxed 24 h post-treatment. Data represent the mean of
three independent experiments, and at least 100 cells were scored for each
experiment.
Human Molecular Genetics, 2011, Vol. 20, No. 11 2177increased p-CHK1 in untreated cells (Fig. 1E). This CHK1
overactivation may be detrimental for FA patients; recently,
an ‘FA-M’ patient was identiﬁed who did not display classical
symptoms of FA and presented with bi-allelic mutations in
both FANCA and FANCM (59). The brother of this patient
carried only bi-allelic mutations in FANCA and developed
‘typical’ FA. It is tempting to speculate that the mild pheno-
type of the ‘FA-M/FA-A’ patient is due to the compensatory
Figure 5. Phosphorylated CHK1 is degraded in a DDB1-dependent manner in the absence of USP1. (A) U2OS cells were transfected with the indicated siRNAs,
treated 72 h later with UVC (10 J/m
2) and lysed 4 h later. Proteins were analysed by western blot with the indicated antibodies. (∗) indicates a nonspeciﬁc band
recognized by the anti-p345 CHK1 antibody. CLS and U1 indicate CLASPIN and USP1, respectively. (B) HeLa cells transfected with the indicated siRNAs were
treated with MMC (2 mg/ml/1 h) or UVC (10 J/m
2) and lysed 20 h and 4 h later, respectively. The lysates were analysed by western blot with the indicated
antibodies. U1 and D1 indicate USP1 and DDB1, respectively. (C) U2OS cells transfected with Ctrl or USP1 siRNAs were treated with DMSO or the proteasome
inhibitor MG132 (10 mM) for 6 h. The cellular extracts were analysed by western blot using the indicated antibodies. (D) Endogenous CHK1 was immunopre-
cipitated from HEK293T cells that were untreated or treated with HU (5 mM; 4 h), and its association with DDB1 was analysed by western blot. (E) The lysates
from HeLa cells transfected with the indicated siRNAs were analysed by immunoblotting to monitor CDT1 levels. DDB1 inhibition stabilized CDT1 while USP1
depletion had no effect. (F) HeLa cells transfected with Ctrl or USP1 siRNAs were treated with MMC (2 mg/ml/1 h) and lysed 20 h later. While USP1 depletion
signiﬁcantly reduced p-CHK1 and protein levels, it did not enhance the degradation of CDT1. (G) A model illustrating the major molecular mechanisms involved
in CHK1 regulation and USP1 participation in this phenomenon. The FANCcore complex was voluntarily excluded from the schema to simplify the ﬁgure.
2178 Human Molecular Genetics, 2011, Vol. 20, No. 11effect of the mutations in FANCM. Because FANCM is
required for efﬁcient ATR/CHK1 activation independently of
the FANC complex (60), we propose that an overactivation
of CHK1, triggered by FANCA mutations, is compensated
for by FANCM deﬁciency, leading to normal CHK1 activity
and a mild FA phenotype. The same hypothesis could be
evoked for all FA patients presenting with a mild clinical phe-
notype or who develop bone marrow failure later in life, as
proposed in a recently published study (61). Thus, bi-allelic
FANC mutations could be associated with a partial impairment
of CHK1 activation or activity resulting in a better outcome
for these patients.
MATERIALS AND METHODS
Cell culture and drugs
HeLa cells, U2OS, HEK293T, FA cells (PD20, PD331 and
PD352) and wild-type SV40-immortalised MRC5 ﬁbroblasts
were routinely grown in DMEM (Gibco) supplemented with
10% fetal calf serum (Dutcher), 2 mM glutamine, 1 mM
sodium pyruvate, 100 U/ml penicillin and 100 mg/ml strepto-
mycin (all from Gibco) at 378Ci n5 %C O 2. MRC5 stably
expressing CHK1–FLAG cells were selected and maintained
in G418-containing medium (400 mg/ml). HEK293T cells
were transfected with the chicken FANCD2 constructs pre-
viously described (45), and clones were selected using
Zeocin. DT40 cells were grown in the same medium described
above but supplemented with 1% chicken serum and 50 mM
b2-mercaptoethanol (45). Genotoxic treatments were per-
formed as previously described (5).
Transfections
Single siRNAs were purchased from Eurogentec. The follow-
ing sequences were used: Ctrl (CGUCGACGGAAUACUUC
GATT), FANCA (GGGUCAAGAGGGAAAAAUATT), and
USP1a (CGACAGCUAUGGAUUAUUUTT) and USP1b
(GAGAAGGACUUUCUGAAUUTT) used as a mix. Lucifer-
ase (used as a control in a few experiments), FANCD2 and
CLASPIN siRNAs were previously described (5). DDB1 and
FANCC smartpool siRNAs were obtained from Dharmacon.
Transfection of siRNA (usually at 100 nM) was performed
with Oligofectamine (Invitrogen), and experiments were
carried out 48–72 h later. In the case of double transfection,
the same total amount of siRNA was used by adding control
siRNA to the single siRNA of interest. The CHK1 construct
was transfected in U2OS cells with Lipofectamine LTX (Invi-
trogen) according to the manufacturer’s instructions. In a few
experiments, siRNA transfections were performed with Inter-
ferin (Polyplus Transfection) at a concentration of 20 nM.
Cell extracts and antibodies
Cells were washed in ice-cold PBS and disrupted in lysis
buffer [50 mM Tris pH 7.9, 150 mM NaCl, 1 mM EDTA and
0.5% NP-40, supplemented with protease and phosphatase
inhibitors (Roche)]. After 20 min of incubation on ice,
lysates were combined with 4X Laemmli buffer containing
b2-mercaptoethanol, sonicated, denaturated by boiling and
separated by SDS–PAGE. The antibodies used were directed
against FANCD2, RAD17, CHK1, actin, NBS1 and PCNA
(Santa Cruz Biotechnology); FANCD2, RPA32, SMC1,
p966SMC1 and vinculin (Abcam); p645RAD17, p345CHK1
and p343NBS1 (Cell Signalling); p68CHK2 and RPA32 (Cal-
biochem); CLASPIN, FANCI, DDB1 and CDT1 (Bethyl); and
gH2AX (Upstate). Antibodies that had been produced and
kindly provided by the Fanconi Anemia Research Fund were
also used against USP1 (D3598) and FANCA (D5300 and
D6512). Signals were detected by the Gene-Gnome apparatus,
and their intensities were quantiﬁed using the Genetools
(Syngene Bio Imaging) software or Image J.
Immunoﬂuorescence
Cells grown on glass cover slips were ﬁxed in 4% paraformal-
dehyde for 15 min before permeabilization in 0.5% Triton
for 5 min. After blocking in 5% BSA, cells were stained
with antibodies against FANCD2 (Abcam ab2187; 1/1000)
and gH2AX (Upstate; 1/2000) for 1 h in IF buffer (0.5%
Tween 20, 12% BSA, 0.036% NaN3 in PBS). Primary anti-
body detection was achieved by incubation with donkey anti-
rabbit Alexaﬂuor 594 and donkey anti-mouse Alexaﬂuor 488
secondary antibodies (Molecular Probes; 1/1000) for 1 h at
room temperature. Slides were mounted in Vectashield con-
taining DAPI (Vector Laboratories) and examined at a magni-
ﬁcation of ×100 using a ﬂuorescence microscope (Olympus).
Only nuclei showing more than ﬁve discrete FANCD2 foci
were considered as FANCD2 foci-positive.
Co-immunoprecipitation
HEK293T cells were seeded in 100 mm Petri dishes and trans-
fected with the indicated siRNAs. Three days later, cells were
treated for 4 h with HU (5 mM) and were disrupted in lysis
buffer. Lysates were clariﬁed with protein G/agarose and
normal mouse IgG (Santa Cruz Biotechnology). Immunopreci-
pitation was performed on 1–2 mg of cell lysates using 2 mg
of monoclonal anti-CHK1 (G4) antibody captured with
protein G/agarose. Immunoprecipitates were washed four
times in lysis buffer before eluting the beads in Laemmli
buffer. To avoid cross-reactions with the IgG heavy chains,
a secondary antibody that does not recognize denaturated
IgG (TrueBlotTM; eBioscience) was used to detect CHK1.
Anti-FLAG beads (Sigma) were also used to immunoprecipi-
tate exogenous FLAG-tagged CHK1.
Repair of UV-induced DNA lesions
Genomic DNA was extracted using the NucleoSpin Tissue kit
(Macherey-Nagel) before denaturation for 5 min at 958C. Dot
blotting on Nylon membranes was performed with 200 ng of
DNA for detection of 6-4 PP. Membranes were incubated in
0.4 N NaOH for 20 min at room temperature before
blockingin5%non-fatdriedmilkinPBS-T.Anantibodyrecog-
nizing 6-4 PP was used at 1/2000 (Cosmo Bio), and
anti-single-stranded DNA was used as a loading control
(Chemicon).
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